| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 19.6 | 29.3 | 22.3 |
| Other income | 0.4 | 1.3 | 0.8 |
| Total income | 20.0 | 30.7 | 23.1 |
| Profit before exceptional items & tax | 0.8 | 6.4 | 2.3 |
| Profit before tax | 0.8 | 6.4 | 2.3 |
| Net profit | 0.9 | 4.8 | 1.7 |
| Operating margin | 4.0% | 20.8% | 10.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -47.10% |
|---|---|
| Net profit, quarter on quarter | -81.20% |
| Revenue, year on year | -12.10% |
NSE results filing, NSE: PAR. Figures extracted from the filing.
Par Drugs & Chemicals Ltd: key numbers
- Share price
- ₹122.74
- Market cap
- ₹151.0 Cr
- Revenue (annual)
- ₹103.7 Cr
- Net profit (annual)
- ₹13.11 Cr
- P/E (TTM)
- 10.4×Sector 47.4×
- Promoter holding
- 73.41%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Par Drugs & Chemicals Ltd
All →Par Drugs & Chemicals Management Change
Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.
Par Drugs & Chemicals Other Announcement
Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.
Par Drugs & Chemicals Management Change
Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.
Par Drugs & Chemicals Annual General Meeting
Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.
Par Drugs & Chemicals Q4 FY26 Results: Net Profit ₹13.1 Cr, Down 2.2% YoY
Par Drugs & Chemicals Ltd reported revenue from operations of ₹103.7 Cr (+2.7% YoY) and net profit of ₹13.1 Cr (-2.2% YoY) for Q4 FY26.
- Key figure
- Net profit ₹13.1 Cr · -2.2% YoY